AI Engines For more Details: Perplexity Kagi Labs You
Antiprotozoal Agent: Quinacrine has historically been used as an antiprotozoal medication, particularly for the treatment of malaria caused by Plasmodium species. However, due to the development of more effective and safer antimalarial drugs, such as chloroquine and artemisinin-based combination therapies, quinacrine is rarely used for this purpose today.
Antiparasitic Agent: Quinacrine has also been used for the treatment of certain parasitic infections, including Giardia lamblia and tapeworm infections. It is sometimes employed as an alternative therapy when other medications are ineffective or unavailable.
Antirheumatic Agent: Quinacrine has been investigated for its potential role in the treatment of autoimmune diseases, particularly rheumatoid arthritis and lupus erythematosus. It is believed to exert immunomodulatory effects by inhibiting the activity of phospholipase A2 and altering lysosomal function. However, its use in rheumatic conditions has declined over time due to the availability of more effective and safer alternative treatments.
Anticancer Agent: Quinacrine has demonstrated anticancer properties in preclinical studies, including inhibition of tumor growth and induction of apoptosis (programmed cell death) in cancer cells. It has been investigated as a potential treatment for various types of cancer, including breast cancer, ovarian cancer, and leukemia. However, further research is needed to determine its efficacy and safety in clinical settings.
Antiviral Agent: Quinacrine has been studied for its antiviral activity against certain viruses, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV). It has been shown to inhibit viral replication in vitro, but its clinical utility for the treatment of viral infections remains uncertain.
Immune Modulation: Quinacrine has been investigated for its immunomodulatory effects, including its ability to suppress the production of proinflammatory cytokines and modulate immune responses. These properties may have potential applications in the treatment of autoimmune and inflammatory diseases, although more research is needed to fully understand its mechanisms of action and therapeutic potential.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.6 | 0.3 | 14.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.1 | 2.2 | 0.41 |
| Allergies | 4.9 | 2.1 | 1.33 |
| Allergy to milk products | 1.2 | 1.6 | -0.33 |
| Alopecia (Hair Loss) | 1.5 | 1.5 | |
| Alzheimer's disease | 5.4 | 6.3 | -0.17 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 0.3 | 8.33 |
| Ankylosing spondylitis | 4.1 | 1.5 | 1.73 |
| Anorexia Nervosa | 1 | 2.6 | -1.6 |
| Antiphospholipid syndrome (APS) | 1.8 | 0.3 | 5 |
| Asthma | 5 | 2.1 | 1.38 |
| Atherosclerosis | 2.1 | 1.7 | 0.24 |
| Atrial fibrillation | 3.3 | 3.1 | 0.06 |
| Autism | 7.6 | 9 | -0.18 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.8 | 1.8 | |
| Bipolar Disorder | 1.6 | 0.8 | 1 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.6 | 2.8 | -3.67 |
| Carcinoma | 4.2 | 2.2 | 0.91 |
| Celiac Disease | 2.7 | 3 | -0.11 |
| Cerebral Palsy | 0.9 | 0.8 | 0.13 |
| Chronic Fatigue Syndrome | 3.6 | 6 | -0.67 |
| Chronic Kidney Disease | 4.1 | 2.3 | 0.78 |
| Chronic Lyme | 0.7 | 0.8 | -0.14 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 1.7 | 0.06 |
| Chronic Urticaria (Hives) | 1.2 | 1.2 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 0.8 | 1 |
| Cognitive Function | 2.2 | 1.4 | 0.57 |
| Colorectal Cancer | 6.1 | 2.3 | 1.65 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 2.4 | 2.6 | -0.08 |
| COVID-19 | 8.1 | 10.8 | -0.33 |
| Crohn's Disease | 8.1 | 4.9 | 0.65 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 0.9 | 1.8 | -1 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 2.4 | 1.1 | 1.18 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 10.4 | 8.9 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 2.5 | -0.39 |
| Endometriosis | 3.1 | 1.7 | 0.82 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3 | 1.7 | 0.76 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 2.9 | 2.4 | 0.21 |
| Functional constipation / chronic idiopathic constipation | 5.5 | 3.6 | 0.53 |
| gallstone disease (gsd) | 3.1 | 1.1 | 1.82 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 0.6 | 2 |
| Generalized anxiety disorder | 2.7 | 1.8 | 0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 0.3 | 3 |
| Graves' disease | 1.3 | 2.6 | -1 |
| Gulf War Syndrome | 0.6 | 1.5 | -1.5 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 2.6 | 1.2 | 1.17 |
| Heart Failure | 4.2 | 1.4 | 2 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 0.9 | 0.3 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.5 | 1 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 3.7 | 5.5 | -0.49 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 2.5 | 0.3 | 7.33 |
| IgA nephropathy (IgAN) | 1.3 | 3.7 | -1.85 |
| Inflammatory Bowel Disease | 7.5 | 8 | -0.07 |
| Insomnia | 2.1 | 1.7 | 0.24 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 1 | 0.6 | 0.67 |
| Irritable Bowel Syndrome | 6.3 | 4 | 0.57 |
| ischemic stroke | 2.2 | 1.7 | 0.29 |
| Liver Cirrhosis | 6.6 | 3.2 | 1.06 |
| Long COVID | 7 | 6.5 | 0.08 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 0.6 | 1.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.6 | 1.5 |
| ME/CFS with IBS | 0.9 | 1.9 | -1.11 |
| ME/CFS without IBS | 0.9 | 2.4 | -1.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.9 | 0.5 | 2.8 |
| Metabolic Syndrome | 7.1 | 7.4 | -0.04 |
| Mood Disorders | 9 | 7.1 | 0.27 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 4.7 | 5.4 | -0.15 |
| Multiple system atrophy (MSA) | 0.6 | 0.3 | 1 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 3.1 | -3.1 | |
| Neuropathy (all types) | 0.3 | 2.2 | -6.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.1 | 3.9 | 0.31 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.6 | 0.5 |
| Obesity | 9.5 | 8.1 | 0.17 |
| obsessive-compulsive disorder | 4.8 | 3.5 | 0.37 |
| Osteoarthritis | 2.7 | 0.9 | 2 |
| Osteoporosis | 1.4 | 1.2 | 0.17 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 6.2 | 7.1 | -0.15 |
| Polycystic ovary syndrome | 5.9 | 2 | 1.95 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 0.9 | 1.5 | -0.67 |
| Primary sclerosing cholangitis | 1.3 | 1.9 | -0.46 |
| Psoriasis | 2.6 | 3.4 | -0.31 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.6 | 4.1 | 0.85 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 4.9 | 2.1 | 1.33 |
| scoliosis | 0.6 | 0.4 | 0.5 |
| Sjögren syndrome | 2.2 | 3.2 | -0.45 |
| Sleep Apnea | 1.7 | 1.1 | 0.55 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.6 | 1.5 |
| Stress / posttraumatic stress disorder | 2.7 | 2.1 | 0.29 |
| Systemic Lupus Erythematosus | 4 | 2 | 1 |
| Tic Disorder | 0.9 | 1.8 | -1 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3 | 3.7 | -0.23 |
| Type 2 Diabetes | 8.5 | 6.5 | 0.31 |
| Ulcerative colitis | 5 | 6.8 | -0.36 |
| Unhealthy Ageing | 5.5 | 2.4 | 1.29 |
| Vitiligo | 2.2 | 1.3 | 0.69 |
